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Abstract 
 
Retinoblastoma Binding Protein 6 (RBBP6) is a multi-domain protein that uses its 
ring finger domain to interact with p53 and pRb tumour suppressor genes. The 
mechanism by which RBBP6 uses to degrade p53 is still unknown. Nonetheless, it 
is well known that RBBP6 promotes cell proliferation in several cancers by 
negatively regulating p53 via its E3 ubiquitin ligase activity (Ntwasa, 2008). 
Degradation of p53 by RBBP6 may compromise p53-mediated apoptosis in breast 
cancer.  
 
This study is intended to investigate the potential applications of RNA interference 
(RNAi) to block RBBP6 expression as well as its subsequent effect on cell growth 
and apoptosis. To achieve these methodologies, the following techniques were 
used: RT-PCR, western blotting, xCELLigence system and flow cytometry. Our 
studies indicate that the knockdown of RBBP6 expression by siRNA modulates 
p53 gene involved in cell death pathways and apoptosis, showing statistically 
significant gene expression differences.  RBBP6siRNA significantly reduced cell 
index (CI) compared to the control samples and we observed an inhibition of 
cellular proliferation in the interval of between 24 and 48 h, as shown in the data 
obtained by dynamic evaluation using the xCELLigence System.  These results 
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were further confirmed by flow cytometry which showed some apoptotic activity. 
About 20.7% increase in apoptosis was observed in cells co-treated with RBBP6 
siRNA and camptothecin when compared to camptothecin-only whereas in 
siRBBP6 and Staurosporine treated there was only 8.8% increase in apoptosis. 
These findings suggest that silencing RBBP6 may be a novel strategy to promote 
staurosporine- and camptothecin-induced apoptosis in breast cancer cells. 
 
Keywords: Retinoblastoma Binding Protein 6, staurosporine, camptothecin  
 
 
 
 
 
 
 
 
 
 
 
 
P Moela: MSc Dissertation 
vi 
 
Acknowledgements 
 
I would like to thank my supervisor Dr Lesetja Raymond Motadi for his 
intellectual input, support and guidance throughout my dissertation work. To my 
co-supervisor Ms Mpho Choene, this research would not have been possible 
without your undying help, the good advice, patience, motivation and the immense 
knowledge you have shared with me throughout. 
 
I would also like to thank National Research Foundation (NRF) for their financial 
support. I also acknowledge the School of Molecular and Cell Biology for its 
academic and technical support. Special thanks to my colleagues, Sindiswa and 
Lungile for their kindness, friendship and a great work ethic. 
 
I also deeply thank my mother Rose Moela and my grandmother Mahlake Moela 
for their endless support and patience throughout my academic years. To my sister 
Thabiso, thank you for always being so proud of my achievements. I admire your 
strong influence towards my academia. You instilled in me great words of 
encouragement when I was close to giving up. 
 
 
P Moela: MSc Dissertation 
vii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedication 
I dedicate this dissertation work to my late father and my late younger sister, 
Reuben Sehlangu and Malebo Moela 
P Moela: MSc Dissertation 
viii 
 
Abbreviations 
 
Apaf-1 
Apo1 
APS 
ATM 
ATP 
Bad 
Bax 
BCA 
BCl-2 
Bid 
BLAST 
Bp 
BRCA1/2 
BSA 
Caspase 
CCD 
cdk 
cDNA 
Apoptosis protease-activating factor-1 
Apolipoprotein 1 
Ammonium persulfate 
Ataxia telangiectasia 
Adenine triphosphate 
Bcl-xL/Bcl-2-associated death protein 
Bcl-2-associated death protein 
Bicinchoninic acid 
B cell leukaemia-2 
B cell leukaemia lymphoma-2 
Basic Local Alignment Search Tool 
Base pair 
Breast cancer 1/2 gene 
Bovine serum albumin 
Cysteine aspartic-specific proteases 
Charge-coupled device 
Cyclin-D dependent kinase 
Complementary DNA 
P Moela: MSc Dissertation 
ix 
 
CI 
CPT 
DEPC 
DISC 
DMEM  
DMSO 
DNA 
DNTPs 
dsRNA 
EDTA 
ER 
FACS 
FADD 
Fas 
FasL 
FBS 
FITC 
GAPDH 
HER2 
HRP 
Cell index 
Camptothecin 
Diethyl pyrocarbonate 
Death signalling complex 
Dulbecco’s modified medium 
Dimethyl sulfoxide 
Deoxyribonucleic acid 
Deoxyribonucleotides 
Double-stranded RNA 
Ethylene diamine tetra acetic acid 
Estrogen receptor 
Fluorescence activated cell sorter 
Fas-associated death domain 
Fibroblast-associated 
Fas Ligand 
Foetal bovine serum 
Fluoresceine-isothiocyanate 
Glyceraldehyde 3-phosphate dehydrogenase 
Human Epidermal growth factor receptor 2 
Horseradish peroxidase 
P Moela: MSc Dissertation 
x 
 
Kb 
kDa 
l 
MDM2 
MOPS 
mRNA  
MW 
NHL 
P2P-R 
P53/TP53 
PACT 
PAGE 
PBS 
PCR 
PI 
PR 
pRB 
PS 
PTEN 
PTGS 
Kilobase 
Kilo Dalton 
Litre 
Murine Double Minute 2 
4-Morpholine-propanesulfonic acid 
Messenger RNA 
Molecular Weight 
Non-hodgkin lymphoma 
Proliferation potential protein-related 
Protein 53/tumor protein 53 
P53-associated cellular protein testis-derived 
Polyacrylamide gel electrophoresis 
Phosphate buffered saline 
Polymerase chain reaction 
Propidium Iodide 
Progesterone receptor 
Retinoblastoma protein 
Phosphatidyl serine 
Phosphate and tension gene 
Post transcriptional gene silencing 
P Moela: MSc Dissertation 
xi 
 
PVDF 
RBBP6 
RING 
RIPA 
RISC 
RNA 
RNAi 
RTCA 
RT-PCR 
SDEV 
SDS 
siRNA 
ssRNA 
STS 
TEMED 
TNF 
TRAIL 
V 
WHO 
Polyvinylidene difluoride 
Retinoblastoma binding protein 6 
Really interesting new gene 
Radioimunoprecipitation  assay 
RNA-induced silencing complex 
Ribonucleic acid 
RNA interference 
Real time cell analyser 
Reverse transcription PCR 
Standard deviation 
Sodium dodecyl sulphate 
Short interfering RNA 
Single-stranded RNA 
Staurosporine 
    N,N, N’, N’-Tetramethylethylenediamine 
Tumour necrosis factor 
TNF-related apoptosis-inducing ligand 
Volts 
World health organisation 
 
P Moela: MSc Dissertation 
xii 
 
Contents 
Declaration ................................................................................................................ ii 
Research Outputs ..................................................................................................... iii 
Abstract .................................................................................................................... iv 
Acknowledgements .................................................................................................. vi 
Dedication ............................................................................................................... vii 
Abbreviations ......................................................................................................... viii 
Figures ......................................................................................................................xv 
Chapter 1: Introduction and Literature Review ...................................................... 1 
1.1.1 Breast Cancer Epidemiology ...................................................................... 2 
1.1.2 Breast Cancer Risk Factors ......................................................................... 3 
1.2 The Cell Cycle .................................................................................................. 6 
1.2.1 Regulation of the cell cycle ........................................................................ 8 
1.3 Apoptosis .......................................................................................................... 9 
1.3.1 Mechanisms of Apoptosis .......................................................................... 9 
1.3.2 Bcl-2 Family Proteins ...............................................................................11 
1.3.3 p53 ............................................................................................................12 
1.3.4 p53 and MDM2 .........................................................................................12 
P Moela: MSc Dissertation 
xiii 
 
1.4 RBBP6 ............................................................................................................15 
Chapter 2: Aim and Objectives .............................................................................17 
Chapter 3: Materials and Methods ........................................................................19 
3.1 Materials ......................................................................................................19 
3.1.1 Cell lines ...................................................................................................19 
3.1.2 Primers ......................................................................................................19 
3.1.3 RNAi Oligos .............................................................................................20 
3.1.4 Staurosporine ............................................................................................21 
3.1.5 Camptothecin ............................................................................................22 
3.2 Methods .......................................................................................................23 
3.2.1 Cell culture routine ...................................................................................23 
3.2.2 RNA interference (RNAi) ........................................................................23 
3.2.3 RNA Extraction ........................................................................................25 
3.2.4 Reverse Transcription ...............................................................................26 
3.2.5 Real Time RT-PCR ..................................................................................27 
3.2.6 Western Blot .............................................................................................29 
3.2.7 xCELLigence System ...............................................................................32 
P Moela: MSc Dissertation 
xiv 
 
3.2.7 Flow Cytometry ........................................................................................33 
3.2.8 Statistical analysis .....................................................................................35 
Chapter 4: Results .................................................................................................36 
4.1. PCR Amplification of Target Genes ..........................................................36 
4.2 Gene Silencing and mRNA Expressional Analysis ....................................37 
4.3 Protein Expression by Western Blot Analysis.............................................45 
4.4 Analysis of Cell Growth after Co-treatment ...............................................52 
4.5 Apoptosis Detection.....................................................................................56 
Chapter 5: Discussion and Conclusions ...............................................................71 
Chapter 6: References ...........................................................................................78 
 
 
 
 
 
 
 
 
 
 
 
 
 
P Moela: MSc Dissertation 
xv 
 
Figures 
 
Figure 1’: The stages of cell cycle and the sites of the regulatory cyclin/CDK……. 
Figure 2’: A diagrammatic representation of p53, MDM2, RBBP6interactions........ 
Figure 3’: Agarose gel electrophoresis showing PCR amplification of target genes. 
Figure 1.1a: Relative quantification of gene expression in MCF-7 cells…………... 
Figure 1.1b: Relative quantification of gene expression in CAMA-1 cells………... 
Figure 1.2: Relative quantification of bax/bcl2 genes in MCF-7 and CAMA-1…… 
Figure 1.3: Relative quantification of gene in MRC-5 cells performed using ……... 
Figure 1.4: Relative quantification of GAPDH in MCF-7, CAMA-1 and MRC-5…  
Figure 2.1: Protein expression in MCF-7 performed using western blot technique... 
Figure 2.2: Protein expression in CAMA-1 and MRC-5 performed by western blot 
Figure 2.3: Protein expression in CAMA-1 and MRC-5 performed by western blot 
Figure 2.4: Protein expression in CAMA-1 and MRC-5 performed by western blot 
Figure 2.5: Protein expression in CAMA-1 and MRC-5 performed by western blot 
Figure 3.1 Cell growth of MCF-7 monitored using xCELLigence system………… 
Figure 3.2: Cell growth of CAMA-1 monitored using xCELLigence system……... 
Figure 3.3: Cell growth of MRC-5 monitored using xCELLigence system………... 
Figure 4: Apoptosis of MCF-7 analysed using flow cytometry……………..……... 
Figure 5: Apoptosis of MCF-7 analysed using flow cytometry……………..……... 
07 
14 
38 
42 
43 
44 
45 
46 
49 
50 
51 
52 
53 
56 
57 
58 
62 
63 
P Moela: MSc Dissertation 
xvi 
 
Figure 6: Apoptosis of MCF-7 analysed using flow cytometry……………..……... 
Figure 7: Apoptosis of CAMA-1 analysed using flow cytometry………………….. 
Figure 8: Apoptosis of CAMA-1 analysed using flow cytometry………………….. 
Figure 9: Apoptosis of MRC-5 analysed using flow cytometry……………..……... 
Figure 10: Apoptosis of MRC-5 analysed using flow cytometry…………………... 
Figure 11: Statistical analysis of flow cytometry in MCF-7 and CMA-1…...……... 
Figure 11: Statistical analysis of flow cytometry in MCF-7……………………….. 
Figure 12: Statistical analysis of flow cytometry in CAMA-1....…………………... 
Figure 13: Statistical analysis of flow cytometry in MRC-5…...…………………... 
 
64 
65 
66 
67 
68 
69 
70 
71 
72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P Moela: MSc Dissertation 
1 
 
                     Chapter 1: Introduction and Literature Review 
 
1. Introduction 
1.1 Breast Cancer 
Breast cancer, characterised by tumorigenic growth in breast tissue, is the 
most prevalent type of cancer in women than in men (Ly et al. 2013). Breast 
cancer is classified into three subtypes according to the presence or absence 
of certain cancer cell receptors (Tinoco et al. 2013). These include the 
hormone receptor (HR) subtype (estrogen and/or progesterone receptors) 
which accounts for nearly 60% of all breast cancer incidences, the oncogene 
human epidermal growth factor receptor 2 (HER2/neu) subtype of which 
20% is observed in all breast cancer cases and the triple negative breast 
cancer (negative for the expression of estrogen, progesterone and HER2/neu 
receptors) which also constitutes about 20% of all breast cancer cases 
(Tinoco et al. 2013). 
 
The estrogen receptor positive breast cancers are the most common types of    
breast cancer because the estrogen and progesterone hormones are playing 
primary roles as transcription factors that mediate breast tumorigenesis, thus 
enabling the recurrence of the disease even after an effective targeting of the 
ER signalling (Lim, Metzger and Winer 2012).  
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In addition to the receptor-associated subtypes of breast cancer, researchers 
have documented intrinsic molecular subtypes: Luminal A and B, and 
HER2-like subsets (Tinoco et al. 2013); (Lim et al. 2012). These molecular 
subtypes correlate with the expression of ER, PR and HER2 in 
approximately 70% of breast cancer cases (Perou et al. 2000); (Sotiriou and 
Pusztai 2009). 
 
 1.1.1 Breast Cancer Epidemiology 
Breast cancer is the most common cancer type amongst women, accounting 
for most cancer deaths second to cervical cancer worldwide (Jemal et al. 
2012). Breast cancer incidence rate (number of people per 100 000 who 
develop breast cancer during a given time period) differs much across the 
world and this remarkable variance is attributed to substantial regional 
differences in the prevalence and distributions of socio-economic factors 
(Jemal et al. 2012). A highest incidence rate of 99.4 per 100 000 people in 
North America alone was observed (WHO, 2013). Moderately increasing 
incidence rates are observed in Europe, other parts of America as well as in 
the Southern Africa (WHO, 2008).  
 
Mortality rates (number of people per 100 000 who die of breast cancer 
during a given time period) amongst women were estimated at 69% 
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worldwide (~519 000 deaths) in 2004 (WHO, 2004). Breast cancer survival 
rate (number of people per 100 000 who die of breast cancer during a given 
time period) is lower in black women (75%) than in white women (89%) as a 
result of poor prognosis in black women (Hortobagyi et al. 2005). This is 
because black women often present with late stage breast cancers with large 
and more aggressive tumours (Ghafoor et al. 2003). 
 
The World Health Organisation statistics for the year 2010 indicate a steady 
increase of breast cancer cases worldwide where about 380 000 deaths are 
observed each year (WHO, 2010). In Africa, 92 600 breast cancer cases and 
50 000 deaths were reported in 2008 statistics, with Southern African women 
showing highest breast cancer incidence rates when compared to women 
from all African countries (Jemal et al. 2012). The United Kingdom’s 
incidence and mortality rate as a result of breast cancer, however, ranks the 
highest in the world with approximately 14000 deaths each year 
(McPherson, Steel and Dixon 2000).  
 
  1.1.2 Breast Cancer Risk Factors 
In a study published by (Steiner, Klubert and Knutson 2008), breast cancer 
risk factors are divided into non-modifiable and modifiable factors. 
Advanced age and female gender are the major non-modifiable risk factors 
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associated with breast cancer and this is due to the fact that the patient’s 
lifetime exposure to female hormones (progesterone and estrogen) associated 
with breast cancer would have increased significantly (Steiner et al. 2008). 
Other important non-modifiable breast cancer risk factors are menarche 
before the age of 12, menopause after the age of 45, genetic mutations and 
family history (Steiner et al. 2008; Nelson et al. 2012; Butt et al. 2012). 
 
Women with first degree relatives demonstrate higher risk of developing 
breast cancer and the risk is much higher in women with first degree 
relatives who are diagnosed at a younger age compared to older first degree 
relatives (Nelson et al. 2012). Breast cancer cases arising from genetic 
mutations account for only about 5% and 60% of inherited breast cancers as 
a result of BRCA1 and BRCA2 gene mutations (Steiner et al. 2008).  
 
Three ‘hot spot’ BRCA gene mutations (BRCA1-185delAG, BRCA1-
5382insC and BRCA2-6174delT) have been identified as highly common in 
Ashkenazi Jewish population, making inherited breast cancer more prevalent 
in this descent group (Dumitrescu and Cotarla, 2005); (Steiner et al. 2008). 
Other genes known to contribute to breast cancer development are p53, 
PTEN (phosphate and tension gene) and ATM (ataxia-telangiectasia) 
(Dumitrescu and Cotarla, 2005).  
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Breast cancer risk factors that can be controlled (or modified) have also been 
documented (Steiner et al. 2008). Hormone therapy (hormone replacement 
therapy or oral contraceptives) use does not alleviate the risk of developing 
breast cancer. However, the risk becomes higher (30-50%) when usage 
exceeds five years (Hulka and Moorman 2008).  
 
Pregnancy and breast feeding are also important risk factors of breast cancer 
that can be controlled (Steiner et al. 2008). Women (white and African-
American) who give birth as early as 20 years of age or younger after a full 
term pregnancy and breast feed have a reduced lifetime risk of developing 
breast cancer when compared to nulliparous women (Ursin et al. 2004); 
(Lord et al. 2008); (Steiner et al. 2008). 
  
Women with high breast density (amount of breast and connective tissue 
compared to fat) have been shown to have a greater risk of developing breast 
cancer (Lokate et al. 2011); (Schreer 2009); (Boyd et al. 2006). Behavioural 
and life style risk factors associated with the development of breast cancer 
include poor diet, i.e. high fat, low vegetable/fruit, low fibre and high in 
simple carbohydrates, overweight and obesity and decreasing physical 
activity (McTireman, 2003). 
 
 
P Moela: MSc Dissertation 
6 
 
    1.2 The Cell Cycle 
The most important function of the cell cycle is to make sure that DNA is   
faithfully replicated in the S-phase and that identical chromosomes are 
equally distributed to two daughter cells during the mitotic (M) phase (Sherr, 
1996). There are four coordinated processes involved in the eukaryotic cell 
cycle, namely cell growth, DNA replication process (or the interphase), the 
segregation of replicated chromosomes into two separate cells (or mitotic 
phase) and cell division (cytokinesis)  (Vermeulen, Van Bockstaele and 
Berneman 2003) and (Cooper, 2000). 
 
A typical human cell divides approximately every 24 hours and even though 
mitosis is the most dramatic stage of the cell cycle, it only lasts about an hour 
while the interphase takes up about 95% of the cell cycle duration during 
which cell growth and DNA replication occur in preparation for cell division 
(Cooper, 2000) 
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Figure 1’: The stages of the cell cycle and the sites of regulatory cyclin/CDK 
complexes (Vermeulen et al. 2003). 
 
The interphase is made up of G1, S and the G2 phase and DNA replication 
takes place in the S-phase which is preceded by the G1 phase where 
preparation of DNA synthesis takes place and is followed by the G2 where 
preparation of cell division or mitosis occurs (Vermeulen et al. 2003). 
Depending on the type of extracellular stimuli, cells in G1 respond by either 
progressing to the S-phase or by entering a quiescent or resting phase called 
G0 where they do not undergo any form of cellular growth  though they are 
metabolically active (Sherr, 1996) and (Vermeulen et al. 2003). 
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Following the interphase is the M-phase where cell division occurs and it is 
divided into four stages, namely the prophase, metaphase, anaphase and 
telophase (Vermeulen et al. 2003).  
 
1.2.1 Regulation of the cell cycle 
Uncontrolled cell proliferation is the basic marker of cancer development and 
most cancers elicit damage in genes that are responsible for the regulation of 
the cell cycle (Sherr, 1996). Serine/threonine protein kinase family members 
known as the cyclin-dependent kinases (CDKs) are the key regulators of the 
transition from one cell cycle phase to another (Vermeulen et al. 2003).  
 
Five CDKs have been identified to be activated during different stages of the 
cell cycle, i.e. CDK 4, 6 and 2 during G1, CDK 2 during the S-phase and 
CDK 1 during G2 and M-phase. Activated CDKs phosphorylate target 
proteins in order to induce downstream processes. CDKs are activated by 
cyclins which are required at different stages of the cell cycle. The type D 
cyclins (cyclin D1, D2, and D3) bind and activate CDK 4 and 6, and cyclin E 
and A bind to CDK 2. In addition to cyclin binding, CDKs are activated by 
phosphorylation at conserved serine/threonine regions and are counteracted 
by CDK inhibitors which bind to either CDKs alone or to CDK/cyclin 
complexes (Vermeulen et al. 2003).  
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1.3 Apoptosis 
Chemotherapy has been a successful tool in the treatment of cancers such as 
testicular cancer and leukaemia. However, its cytotoxic effects have collateral 
damage to normal cells when used in the treatment of epithelial cancers such 
as breast, cervical, colon or lung (Johnstone, Ruefli and Lowe 2002). This, 
together with the fact that cancer cells have the ability to avoid apoptosis and 
continue proliferating, have led to current approaches in cancer therapy to 
focus on killing tumorigenic cells through the induction of apoptosis (Debatin 
2004) 
 
Apoptosis, as first described by Kerr et al. (1972), is a form of programmed 
cell death characterized by cell morphological changes that include blebbing, 
cell shrinkage, nuclear fragmentation, chromatin condensation, chromosomal 
DNA fragmentation and a subsequent cell death (Ouyang et al. 2012). Other 
forms of programmed cell death include autophagy and necrosis which are 
both distinguished from apoptosis by their morphological differences (Bialik 
et al. 2010).  
1.3.1 Mechanisms of Apoptosis  
Apoptosis is comprised of two signalling pathways, namely the death 
receptor pathway (extrinsic) and the mitochondrial pathway (intrinsic), (Wen 
et al. 2012). Activation of the extrinsic pathway is initiated by binding of the 
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Fas Ligand to the cell surface death receptor, Fas, a member of the TNF 
(tumour necrosis factor) receptor superfamily. Other members include the 
tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor, 
Apo-2 and TNF-1 death receptors (Ghobrial, Witzig and Adjei 2005).  
 
The Fas L-Fas complex forms a death inducing signalling complex (DISC) by 
aggregating with the Fas-associated death domain (FADD) adaptor protein 
and pro-caspase-8, thus leading to an active caspase-8 enzyme which 
subsequently activates pro-caspase-3, an enzyme required for execution of the 
apoptosis process (Ouyang et al. 2012). In other cells, caspase-8 interacts 
with death modulators (e.g. Bid) of the intrinsic pathway which lead to the 
release of cytochrome c (Ghobrial et al. 2005). 
 
The intrinsic pathway is regulated by the Bcl-2 family proteins which become 
activated by post translational modifications followed by translocation to the 
mitochondria in response to either extracellular or intracellular stimuli. This 
triggers the release of cytochrome c from the outer mitochondrial membrane 
into the cytoplasm. The cytoplasmic cytochrome c interacts with pro-caspase-
9 and Apaf-1 molecule to form an apoptosome body which leads to an active 
caspase-9 responsible for cleaving pro-caspase-3 into an active caspase-3 
necessary for the induction of apoptosis (Ouyang et al. 2012) and (Ghobrial et 
al. 2005). 
P Moela: MSc Dissertation 
11 
 
      
1.3.2 Bcl-2 Family Proteins 
The Bcl-2 family proteins, first identified in follicular non-Hodgkin 
lymphoma (NHL), are known to control apoptosis at the intrinsic pathway 
level and are highly expressed in many other cancers. Therefore, numerous 
anti-tumour drugs exert their effects on the Bcl-2 proteins (Ghobrial et al. 
2005). This family of proteins is made up of the proapoptotic Bcl-2 proteins 
which promotes apoptosis (Bax, Bak, Bad, Bcl-Xs, Bid and Bik) and the anti-
apoptotic Bcl-2 proteins which suppress apoptosis (Bcl-2, Bcl-XL, Bcl-W, 
Bfl-1 and Mcl-1) (Ghobrial et al. 2005). 
 
The proapoptotic members promote apoptosis by mediating the release of 
cytochrome c from mitochrondria and the anti-apoptotic members block 
apoptosis by inactivating the pro-apoptotic members (Ouyang et al. 2012). 
Bax and Bak are termed BH3-only proteins and they exert their pro-apoptotic 
effects using the BH3 molecule (Ghobrial et al. 2005) and (Ouyang et al. 
2012). In response to cellular stress, the proapoptotic proteins undergo 
activation processes such as dephosphorylation and cleavage followed by 
movement to the mitochondria where they initiate cytochrome c release 
(Ghobrial et al. 2005) and (Ouyang et al. 2012).   
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1.3.3 p53 
The first human cDNA clones of the p53 tumour suppressor gene which 
codes for a protein of 393 amino acid were first isolated in the early 1980’s 
and it was named so because it elicits a band size of 53kDa in agarose gel 
electrophoresis (Nag et al, 2013). The tumour suppressor gene is responsible 
for the regulation of cell cycle arrest, DNA repair and apoptosis and it is 
highly mutated in several cancers, thus leading to deregulation of the cell 
cycle and apoptosis impairment (Ghobrial et al. 2005).  
 
Following nuclear stress such as radiation, p53 activates p21 gene which is 
responsible for the induction of cell cycle arrest during which damaged DNA 
is allowed to undergo repair. However, if damage is irreversible, p53 
activates proapoptotic Bcl-2 protein members in order to induce apoptosis 
although the mechanism by which p53 induces apoptosis is not well 
understood (Ghobrial et al. 2005). 
1.3.4 p53 and MDM2 
Oncogenes and tumour suppressor genes maintain the balance between cell 
growth and cell death and p53 is one of the well-studied tumour suppressor 
genes that plays a role in the development and homeostasis of cells and 
tissues (Jiang et al, 2013). In addition to its downstream effectors such as 
cyclin dependent kinase inhibitor p21, pro-apoptotic bax and tumour necrosis 
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factor receptors (Fas and/or Apo1), p53 transcriptionally activates its negative 
regulator, MDM2, in an autoregulatory feedback loop (Jiang et al, 2013) and 
(de Rozieres et al, 2000).   
   
MDM2 (Murine Double Minute 2) was established as an oncogene in a study 
which demonstrated that overexpression of the MDM2 gene rendered rodent 
fibroblasts tumorigenic in nude mice (Menedez et al, 2009). The MDM2 gene 
codes for a 491 amino acid protein and it contains two transcriptional 
promoter elements, one of which is p53-dependent (Menedez et al, 2009). 
Also known as a family member of the E3 ubiquitin ligases, MDM2 directly 
interacts with p53 to mediate its ubiquitination (Jiang et al, 2013). Following 
its expression, MDM2 translocates from the nucleus to the cytoplasm where it 
mediates the degradation of p53 and other targets (Menedez et al, 2009).  
 
In most cancers, the mutated p53 or the function of wild-type p53 is inhibited 
by the MDM2 oncogene resulting in the impairment of tumour suppressive 
p53-pathways such as apoptosis and cell cycle arrest, thus interfering with the 
p53-MDM2 interaction as a cancer therapeutic strategy may be potential (Nag 
et al, 2013).     
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Figure 2’: A simplified diagrammatic representation of interactions among 
p53, MDM2 and RBBP6. 
Under normal cellular conditions, p53 tumour suppressor gene is kept under 
tight regulation by the MDM2-P53 auto-regulatory feedback loop. In 
response to stress stimuli such as DNA damage or radiation, activated p53 
interacts with genes such as p21, Bax, Noxa and Puma which are responsible 
for the induction of cell cycle arrest and apoptosis as illustrated in figure 2. 
During cancer development, the interaction between p53 and MDM2 
mediates p53 interaction with the ring finger domain of ubiquitin ligases, in 
this case the RBBP6 ubiquitin ligase, for degradation of the p53 tumour 
suppressor protein. This compromises the occurrence of p53-mediated 
apoptosis and facilitates cell proliferation.  
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 1.4 RBBP6 
Screening tests performed over a decade ago revealed Retinoblastoma 
Binding Protein 6 (RBBP6) as a multi-domain protein that uses its ring-
finger domain to interact with the p53 and pRb tumour suppressor genes 
(Pugh et al. 2006); Pretorius et al, 2013). Also known as RBQ-1, PACT or 
P2P-R, the RBBP6 mRNA occurs in the form of three major transcripts, 
transcript 6.1, 6.0 and 1.1kb as a result of alternative splicing which code for 
protein isoforms 1, 2 and 3, respectively (Pugh et al. 2006).  
 
RBBP6 is highly expressed in cancer of the oesophagus as well as other 
cancers and this makes it a potential target in the treatment of cancers with 
intact p53 (Ntwasa, 2008); (Pugh et al. 2006). In addition to its several 
biological functions such as transcription, translation and ubiquitination, it is 
associated with the execution of p53 degradation following inhibition of the 
tumour suppressor gene by MDM2, thus facilitating cell proliferation 
(Ntwasa, 2008); (Pretorius et al, 2013). However, little is known about the 
mechanism by which RBBP6 uses to degrade the p53 tumour suppressor 
protein. 
 
A study performed by Li et al., (2007) indicates that knockdown of RBBP6 
in mice leads to enhanced p53 accumulation which favours apoptosis and a 
slow growth in the mice. RBBP6 is responsible for negatively regulating p53 
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by interacting with MDM2, thus leading to p53 depletion. Silencing RBBP6 
in mice led to an up-regulation of p53 (Li et al., 2007). 
 
Although monotherapy archives a significant response rate in cancer patients, 
drug resistance is still a major hiccup to be addressed in cancer therapy. 
Recently, most of the efficient regimes for anticancer activity include 
multidrug combinations, thus investigating optimum combinations may be 
useful for cancer treatment (Arakawa et al, 2009). RNA interference (RNAi) 
is a regulatory mechanism that uses small interfering RNA (siRNA) 
molecules to degrade specific mRNA and silence gene activity (Aagaard and 
Rossi, 2007). 
 
Camptothecin causes DNA strand breaks during the S-phase of the cell cycle 
by stabilizing DNA-topoisomerase I complexes in order to induce apoptosis 
in cancer cells (Arakawa et al, 2009) and staurosporine induces apoptosis by 
inhibiting protein kinases (Xue et al, 2003).  In this study, we report on 
additive cytotoxic effects between gene therapy (RNA interference) and 
apoptosis-inducing agents (camptothecin and staurosporine) in human breast 
cancer cells. 
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                                  Chapter 2: Aim and Objectives 
 
The aim of this study was to promote the induction of apoptosis in breast 
cancer cells following gene silencing in combination with staurosporine and 
camptothecin treatments. Since RBBP6 is involved in the degradation of p53 
thus reducing p53-mediated apoptosis to facilitate cell proliferation, the 
effect of co-treatment with RBBP6 gene silencing and apoptosis-inducing 
agents on p53 expression was evaluated at both mRNA and protein level.  
 
Objective 1: To silence RBBP6, MDM2 and p53 by transfecting human 
breast cancer cell lines with siRBBP6, siMDM2 and sip53 
  
Objective 2: To check whether RBBP6, MDM2 and p53 genes were 
silenced by measuring gene expression levels using Real Time RT-PCR 
technique 
 
Objective 3: To check the effects of RBBP6 and MDM2 gene silencing on 
the expression of p53 gene using Real Time PCR technique 
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Objective 4: To co-treat human breast cancer cell lines with siRNAs 
(RBBP6, MDM2 and p53) and apoptosis-inducing agents (staurosporine and 
camptothecin) 
 
Objective 5: To confirm gene silencing by measuring protein expression 
levels of RBBP6, MDM2 and p53 using western blot analysis following co-
treatment  
  
Objective 6: To measure expression levels of Bax and BCl-2 following co-
treatment using real time RT-PCR and western blot analysis  
 
Objective 7: To measure cell growth using eXCELLigence system and 
apoptosis using flow cytometry analysis following co-treatment   
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                               Chapter 3: Materials and Methods 
 
3.1 Materials 
3.1.1 Cell lines 
 
Different breast cancer cell lines and a non-tumorigenic cell line were used in 
this study as both a primary source of mRNA and protein and for studying 
growth and morphology after co-treatment.  The cell lines include non-
invasive MCF-7 breast cancer cells, invasive CAMA-1 breast cancer cells 
and MRC-5 lung fibroblasts. All cell lines were obtained from Japan Health 
Resource Centre.     
3.1.2 Primers 
The following primer sequences which were designed using Primer3Plus 
software were used to amplify the corresponding genes: 
 
RBBP6 Primers 
Forward primer:    CAGCGACGACTAAAAGAAGAG 
Reverse primer:     GAGCGGCTGAATGATCGAGA  
 
p53 Primers 
Forward primer:    TGACACGCTTCCCTGGATTG 
Reverse primer:  ACCATCGCTATCTGAGCAGC 
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MDM2 Primers: 
Forward Primer: ATCAGGCAGGGGAGAGTGAT 
Reverse Primer: TCTACATACTGGGCAGGGCT 
 
Bax Primers 
Forward Primer: CCGCCGTGGACACAGAC 
Reverse Primer: CAGAAAACATGTCAGCTGCCA 
 
BCl-2 Primers 
Forward Primer: TCCGATCAGGAAGGCTAGAGTT 
Reverse Primer: TCGGTCTCCTAAAAGCAGGC 
 
GAPDH Primers 
Forward Primer: CAGCCGCATCTTCTTTTGCG 
Reverse Primer: TGGAATTTGCCATGGGTGGA 
3.1.3 RNAi Oligos 
Silencing was archived by the use of Ambion’s Silencer® Select Pre-designed 
siRNAs supplied by Life Technologies™ which target the RBBP6, MDM2 
and p53 genes. The siRNA molecules are chemically modified 21-mer double 
stranded nucleotides that are recognised by the cytoplasmic RNA-induced 
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silencing complex (RISC) of mammalian cells to mediate inactivation of 
target genes (Aagaard and Rossi, 2007). Delivery of the Ambion’s Silencer® 
Select Pre-designed short interfering RNAs into the mammalian adherent 
cells was achieved by the use of the lipid-based siPORT™ NeoFX™ 
transfection agent also manufactured by Ambion
®
. Oligonucleotide targeting 
GADPH served as a positive control and a non-targeting oligonucleotide 
served as a negative control. 
 
3.1.4 Staurosporine 
Chosen as one of the apoptosis-inducing agents in this study, staurosporine 
(Calbiochem
®
) is known for its protein kinase inhibiting property and as a 
strong inducer of apoptotic cell death (Xue et al, 2003). The mechanism by 
which staurosporine uses to induce apoptosis is still controversial. Several 
studies report that the mitochondrial apoptotic pathway plays a central role in 
the staurosporine-induced cell death while other reports show that there is a 
requirement for the activation of caspases in staurosporine-induced 
apoptosis. The protein kinase inhibitor is largely thought to mediate 
translocation of bax to the outer mitochondrial membrane where it 
permeabilises the membrane, thus leading to the release of cytochrome c from 
mitochondria into the cytoplasm (Zhang et al, 2004 and Xue et al, 2003).   
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3.1.5 Camptothecin 
Camptothecin (Calbiochem
®
) is a plant extract isolated from Camptotheca 
acuminata tree which is originally cultivated in most regions of China where 
it is used for anticancer treatment in Chinese traditional medicine. It is 
classified as a quinoline alkaloid that exerts its cytotoxic effects by the 
induction of apoptosis. Camptothecin binds to DNA topoisomerase I complex 
to form a ternary structure that stabilizes the complex to block religation of 
DNA, thus causing DNA strand breaks that result in apoptosis (Nieves-Neira 
and Pommier 1999). 
 
Clinical trials on this apoptosis-inducing agent revealed low solubility and 
adverse drug reactions which led to the synthesis of more soluble and 
beneficial camptothecin derivatives which demonstrate good activity against 
tumours of lung, breast, colorectal and ovarian (Nieves-Neira and Pommier 
1999). Examples are irinotecan hydrochloride and topotecan which have 
been clinically approved by the FDA and are clinically used in anticancer 
therapy (Arakawa et al, 2009).    
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3.2 Methods 
3.2.1 Cell culture routine 
Human monolayer normal and cancer cell lines were grown in HyClone
®
 
DMEM/High Glucose growth medium supplemented with 10% FBS (fetal 
bovine serum) and 1% antibiotic (penicillin/streptomycin) and routinely 
maintained at 37°C in a 5% CO2 incubator. The cells were fed every second 
day of the week by replacing old growth medium with equal amount of fresh 
growth medium after rinsing twice with 2ml PBS. The cells were sub-
cultured when at near-confluency at least once per week and excess sub-
cultures were preserved at ≥ -80°C in DMEM/High Glucose growth medium 
supplemented with 10% FBS and 20% DMSO (dimethyl sulfoxide).   
 
3.2.2 RNA interference (RNAi) 
Principle 
RNA interference (RNAi), also called post transcriptional gene silencing 
(PTGS), is a eukaryotic regulatory mechanism that plays an important role in 
directing development and suppressing parasitic gene expression. It uses 
small interfering RNA (siRNA) molecules to degrade specific mRNA and 
silence gene activity (Aagaard and Rossi, 2007). The RNAi pathway is 
initiated by cleavage of long double stranded RNA by DICER enzyme into 
short interfering double stranded RNA molecules of about 20 nucleotides in 
length. 
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These short interfering RNA molecules have a characteristic 5’phosphate and 
a two nucleotide 3’overhang which allows them to be recognised by the 
RNAi machinery that eventually leads to degradation of target mRNA 
(Meister and Tuschl, 2004). The short double stranded siRNA separates into 
two single stranded RNA (ssRNA) named the guide strand and the passenger 
strand. The passenger strand becomes degraded and the guide strand 
associates with the RNA-induced silencing complex (RISC) where it 
specifically base-pairs with complementary target mRNA. This induces 
catalytic cleavage of the target gene by a component of the RISC complex 
known as Argonaute enzyme (Aagaard and Rossi, 2007 and Meister and 
Tuschl, 2004).  
 
Introduction of artificial siRNAs has been adopted as a tool to target and 
inactivate gene expression both in-vitro and in-vivo. Most human diseases 
such as cancer, viral infections, autoimmune diseases and genetic disorders 
are associated with alterations in one or more genes and therefore this makes 
the RNAi intervension an attractive strategy for gene-related therapeutics 
(Aagaard and Rossi, 2007). In this study, we used RNAi to silence RBBP6, 
MDM2 and p53 in breast cancer cell lines. 
 
Technique 
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Seventy to eighty percent (70-80%) confluent cells were transfected with 
100nM siRNAs targeting RBBP6, MDM2 and p53 over a 24 hour period. 
Briefly, the adherent cells were trypsinized and resuspended in an antibiotic-
free media. The cell suspension was then mixed with siRNA/transfection 
agent complex in a 24-well plate and incubated at 37°C for 24 hours. Post 
transfection cells were exposed to 0.25μΜ staurosporine and 0.25μΜ 
camptothecin for additional 24 and 48 hours and then harvested for 
subsequent analysis. 
3.2.3 RNA Extraction 
Principle 
RNA is used as a starting point for downstream processes such as reverse 
transcription real-time PCR, conventional PCR, array analysis and cDNA 
library constructions. However this single stranded ribonucleic acid is highly 
unstable with a very short half-life once extracted from cells or tissues. It is 
the ubiquitous presence of RNAses on all tissues (especially on skin, in 
blood, and in most bacteria and fungi in the environment) that make RNA 
easily degradable. High quality total RNA is therefore an absolute 
prerequisite in the performance of molecular techniques (Tan and Yiap, 
2009). Most RNA isolation procedures make use of RNAse inhibitory agents 
such as chaotropic ions (e.g. guanidine salt), sodium dodecylsulfate (SDS) 
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denaturant or phenol-based compounds. The commercial RNA isolation kit 
used in this study relies on guanidine chaotropic salt.  
 
Technique 
The general purification steps which were used in this study following a 24, 
48 and 72 hour co-treatment of nearly confluent cultured cells with 
Nucleospin
®
 RNA II total RNA isolation kit include: effective disruption of 
cells → denaturation of nucleoprotein complexes → inactivation of DNAses 
→ washing steps for the removal of salts, metabolites and macromolecular 
cellular components → elution of pure RNA. The resulting RNA was 
quantified using the nanodrop technique and RNA purity was confirmed by 
ensuring that A260/A280 ratio was >1.7 and the RNA integrity was 
confirmed by examination of the 18S and 28S RNA bands on agarose gel 
stained with ethidium bromide. 
 
3.2.4 Reverse Transcription 
Principle 
In order to perform RT-PCR, the obtained RNA template must first be 
converted into a complementary DNA (cDNA) by the use of reverse 
transcriptase enzyme. In this study we performed reverse transcription using 
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the ImProm-II™ Reverse Transcription System commercial kit manufactured 
by Promega.  
 
Technique 
Cells were co-treated with siRNAs and apoptosis-inducing agents for 24, 48 
and 72 hours before RNA isolation. Sequence specific primers (RBBP6, 
MDM2 and p53) designed using the Primer3Plus bioinformatics tool together 
with the obtained total RNA template, formed major components of the PCR 
cocktail used in the synthesis of cDNA. The RNA reverse transcription was 
performed according to the manufacturer’s detailed protocol using the 
Multigene Gradient Thermal Cycler.  
     
3.2.5 Real Time RT-PCR 
Principle 
To check whether the transfected cells were successfully silenced and to 
study gene expression changes following co-treatment of cells, real time RT-
PCR was performed. The total mRNA transcribed into complementary cDNA 
was amplified and quantified by the use of real time polymerase chain 
reaction. Real time RT-PCR differs from conventional PCR in that instead of 
detecting and quantifying amplified DNA at the end of the reaction, the 
amount of PCR product is measured at each cycle in real time.  Measurement 
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of the amount of DNA at each cycle is accomplished by the use of fluorescent 
dyes capable of intercalating each of the newly synthesized double stranded 
DNA to produce a signal that’s directly proportional to the amount of PCR 
product. 
 
SYBR Green is the commonly used fluorescence dye due to its advantages, 
i.e. it is inexpensive, easy to use and highly sensitive. The disadvantage is 
that SYBR Green will bind to any double-stranded DNA in the reaction, 
including primer-dimers and other non-specific reaction products which 
results in an over estimation of the target concentration. Other commonly 
used probes include TaqMan, Molecular Beacons and Scorpions.    
 
Technique 
In this study, the SYBR
®
 Green JumpStart Taq ReadyMix (SIGMA
®
) dye 
was used to quantify the amount of gene expression from cDNA synthesized 
from total RNA that was isolated from cultured cells exposed to 24, 48 and 
72 hour treatment with 100nM siRNAs and 0.25μM apoptosis inducing 
agents. The real time RT-PCR was performed in a 20μl reaction mixture 
containing 2100ng/ul cDNA, SYBR Green, forward and reverse primers. 
(GADPH: Forward – 5’-GAG TCA ACG GAT TTG GTC GT- 3’, Reverse – 
5’-TTG ATT TTG GAG GGA TCT CG- 3’; RBBP6:   Forward – 5’ –CAG 
CGA CGA CTA AAA GAA GAG TCT- 3’, Reverse – 5’ – GGT AAT TGC 
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GGC TCT TGC CT- 3’;  p53: Forward – 5’ -GTT CCG AGA GCT GAA 
TGA GG- 3’, Reverse – 5’ -TGA GTC AGG CCC TTC TGT CT -3’, 
MDM2: forward– 5’ ATCAGGCAGGGGAGAGTGAT_3’ and Reverse– 5’ 
TCTACATACTGGGCAGGGC-3’ under the following conditions: 36 cycles 
of 94°C for 35s, 59°C for 45s, and 72°C for 45s.  
  
3.2.6 Western Blot 
Principle 
Western blot analysis continues to be a routine technique in most laboratories 
to determine the level of expression of proteins. This protein analysis 
technique was introduced by Towbin et al. in 1979. The term blotting refers 
to the transfer of biological samples from a gel to a membrane and their 
subsequent detection on the surface of the membrane. The first step in a 
western blotting procedure is to separate the macromolecules using gel 
electrophoresis. Following electrophoresis, the separated molecules are 
transferred or blotted onto a second matrix, generally a nitrocellulose or 
polyvinylidene fluoride (PVDF) membrane. Next, the membrane is blocked 
to prevent any nonspecific binding of antibodies to the surface of the 
membrane. The transferred protein is complexed with an enzyme-labelled 
antibody as a probe. An appropriate substrate is then added to the enzyme and 
together they produce a detectable product such as a chromogenic or 
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fluorogenic precipitate on the membrane for colorimetric or fluorometric 
detection, respectively.  
 
The most sensitive detection methods use a chemiluminescent substrate that, 
when combined with the enzyme, produces light as a by-product. The light 
output can be captured using film, a CCD camera or a phosphorimager that is 
designed for chemiluminescent detection. Whatever substrate is used, the 
intensity of the signal should correlate with the abundance of the antigen on 
the blotting membrane.  
 
Detailed procedures of a western blot vary widely.  One common variation 
involves direct vs. indirect detection. With the direct detection method, the 
primary antibody that is used to detect an antigen on the blot is also labelled 
with an enzyme or a fluorescence dye. This detection method is not widely 
used as most researchers prefer the indirect detection method. In the indirect 
method, a primary antibody is added first to bind to the antigen. This is 
followed by a labeled secondary antibody that is directed against the primary 
antibody. Labels include biotin, fluorescence probes such as fluorescein or 
rhodamine and enzyme conjugates such as horseradish peroxidase or alkaline 
phosphatase. In this study, the indirect method was used since it offers more 
advantages over the direct method, i.e. it has increased sensitivity, a wide 
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variety of labelled secondary antibodies are available commercially and 
immunoreactivity of the primary antibody is not affected by labeling.   
 
Technique 
Whole cell protein was extracted using RIPA buffer (1% NP-40, 0.5% 
sodium deoxycholate, 10% sodium dodecylsulfate (SDS), and 3 μl/ml 
aprotinin and 5μg/ml leupeptin in PBS, pH 7.4). Seventy two (72) hours post 
transfection and co-treatment with either staurosporine or camptothecin, cells 
were washed twice with cold PBS, then resuspended in 500μl RIPA buffer 
and collected by scraping. The total protein was then separated from cell 
debri by centrifugation at 14000 rpm for 15 minutes followed by 
quantification with Pierce® BCA Protein Assay Kit.  The protein was heated 
at 95°C for 5 minutes and 30μg was loaded per well for electrophoretic 
separation in 40% acrylamide gel preparation at 100V for 1hour. The protein 
was transferred onto a nitrocellulose membrane using wet electro-transfer 
method overnight at 30V followed by incubation with primary antibody after 
1 hour of blocking with 5% non-fat milk buffer. The weak light signal 
produced by HRP-linked secondary antibody was detected and enhanced 
using the Pierce® ECL Western Blotting Chemiluminescence Substrate and 
the blots were imaged by the CCD-based ChemiDoc™ MP system.  
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3.2.7 xCELLigence System 
Principle 
To study the effect of the co-treatment on cellular growth of the studied cell 
lines, the xCELLigence system for real time analysis of mammalian cell was 
used. This label-free assay allows the possibility for real time measurement of 
cellular responses and this eliminates some of the shortcomings of end-point 
assays. The xCELLigence system uses specially designed microtiter plates 
containing interdigitated gold microelectrodes to non-invasively monitor the 
viability of cultured cells using electrical impedance as a read out in the form 
of cell index (CI). 
 
Technique 
Before cells were seeded, 16-well E-plates containing antibiotic-free medium 
were imposed to current flow on the xCELLigence instrument to record 
background readings. 1 x 10
5
 cells were then seeded in each well of the E-
plates simultaneously with 100nM siRNA targeting RBBP6, MDM2 and p53 
genes in the same antibiotic-free medium. The E-plates were connected back 
on current flow supplied by the xCELLigence instrument that was placed in a 
37°C incubator and the experiment was allowed to run for 24 hours. Twenty 
four hours (24) hours post transfection cell were further treated with 0.25μM 
apoptosis-inducing agents (staurosporine and camptothecin). The experiment 
was continued for an additional 24 hours. Cell Index values were recorded at 
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15 minute interval sweeps until the end of the experiment under the following 
xCELLigence parameters: [1st step: 1 sweep, 1 minute interval, 00:00:39 
total time; 2nd step: 100 sweeps, 15 minute interval, 24:45:39 total time; 3rd 
step: 100 sweeps, 15 minute interval, 49:30:39 total time].  
 
3.2.7 Flow Cytometry 
Principle 
To check whether the observed cell death caused by co-treating cultured cells 
with siRNA + apoptosis-inducing agents was as a result of apoptosis and not 
necrosis, flow cytometry analysis technique was used. Loss of plasma 
membrane asymmetry and attachment are the earliest features of apoptosis. In 
early apoptotic cells, the membrane phospholipid phosphatidyl serine (PS) is 
translocated from the inner to the outer leaflet of the plasma membrane, 
thereby exposing PS to the external cellular environment.  
 
Annexin V, a 35-36 kDa Ca
2+
 dependent phospholipid-binding protein that 
has a high affinity for PS, binds to the exposed PS. Annexin V may be 
conjugated to fluorochromes including FITC. This format retains its high 
affinity for PS and thus acts as a sensitive probe for flow cytometric analysis 
of cells that are undergoing apoptosis. Since externalization of PS occurs in 
the earlier stages of apoptosis, FITC Annexin V staining can identify 
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apoptosis at an earlier stage than assays based on nuclear changes such as 
DNA fragmentation. 
 
FITC Annexin V staining precedes the loss of membrane integrity which 
accompanies the latest stages of cell death resulting from either apoptotic or 
necrotic processes. Therefore staining with FITC Annexin V is typically used 
in conjugation with vital dyes such as propidium iodide (PI) to allow 
identification of early apoptotic cells (PI negative, FITC Annexin V positive). 
Viable cells with intact membrane exclude PI whereas the membranes of the 
dead and damaged cells are permeable to PI. Viable cells are considered 
FITC Annexin V and PI negative. Cells that are in early apoptosis are 
considered FITC Annexin V positive and PI negative, and cells that are in late 
apoptosis are considered both FITC Annexin V and PI positive. 
 
Technique 
Cultured cells were seeded in 24-well plates and simultaneously transfected 
with siRNAs targeting RBBP6, MDM2 and p53 for 24hours and treated for 
an additional 24 hours with apoptosis-inducing agents (0.25 μΜ 
staurosporine and camptothecin). The treated cells were then trypsinized, 
transferred to 15 ml tubes, pelleted for 2 minutes at 1500 rpm and 
resuspended in 100µl 1X binding buffer (annexin V-FITC Apoptosis 
Detection Kit, abcam
®
) at a concentration of 1x10
4
 cells/ml. The cell solution 
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was then transferred into 1ml tubes and 5µl of FITC Annexin V and 5µl of PI 
were added. This was followed by gentle vortexing and incubation for 15 
minutes at room temperature in the dark. 400µl 1X binding buffer was then 
added to each tube and the cell solutions were analysed by flow cytometry 
within 1 hour.  
 
3.2.8 Statistical analysis 
The results of each series of experiments (performed in duplicates) are 
expressed as the mean values ± standard deviation of the mean (SD). Levels 
of the statistical significance were calculated using the paired student t-test 
when comparing two groups or by analysis of variance (ANOVA). P-values 
of ≤ 0.05 were considered significant. 
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                                              Chapter 4: Results 
 
 
4.1 Introduction 
Retinoblastoma binding protein 6 (RBBP6) negatively regulates p53 with its 
E3 ubiquitin ligase function and thus promotes cell proliferation. This event 
may in turn compromise the occurrence of p53-mediated apoptosis in breast 
cancer cells. Therefore, in this study we hypothesized that silencing the 
expression of RBBP6 may enhance apoptosis induced by either staurosporine 
or camptothecin. To address this question, RNA interference, real time RT-
PCR, western blotting, xCELLigence system and flow cytometry were used.  
 
4.1. PCR Amplification of Target Genes 
Before cDNA synthesis by reverse transcription could be performed, the 
integrity of total mRNA isolated from MRC-5 fibroblast, MCF-7 and 
CAMA-1 breast carcinomas was evaluated using ethidium bromide-stained 
agarose gel electrophoresis. The synthesized cDNA served as a template in 
the amplification of RBBP6, MDM2, p53, bax, bcl-2 and GAPDH genes as 
shown by agarose gel electrophoresis, amplification of each gene was 
successful at different annealing temperatures (figure 3). 
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Figure 3’: Agarose gel electrophoresis showing amplification of target genes 
in MRC-5 fibroblasts. Lane M represents DNA molecular weight marker and 
lanes 1, 2, 3, 4 and 5 represent amplification of the following genes: RBBP6, 
MDM2, BCl-2, bax, p53, and RBBP6, respectively. 
 
4.2 Gene Silencing and mRNA Expressional Analysis 
 
Gene silencing by RNAi leads to a highly potent repression of gene 
expression mainly because it employs cellular machinery that effectively 
allows targeting of specific mRNA transcripts (Aagaard and Rossi, 2007). In 
this study the RNAi technique was employed to down-regulate RBBP6 and 
its associated genes, namely p53 and MDM2.  To check whether or not gene 
silencing was successful, real time RT-PCR which relies on reverse 
transcription of total RNA to synthesize complimentary DNA that serves as a 
template during real time PCR amplification of the genes of interest was 
used.  
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Quantitative PCR analysis was used to evaluate the transcript on the silenced 
RBBP6, p53, MDM2, and the effect they have on Bax and Bcl2 genes as 
shown in figure 1. As expected we have observed 37% decrease in RBBP6 
expression following silencing of MCF-7 cells with 100nM siRNA while in 
combination with camptothecin the expression was further reduced by about 
49%. In MCF-7 cells that where treated with Staurosporine and siRBBP6, 
expression was reduced by only 22%. In siMDM2, we observed a much 
higher silencing following co-treatment with both staurosporine and 
camptothecin at 50% and 51%, respectively (figure1.1a: A&B).  In CAMA-1 
cells, about 87% and 90% gene silencing of RBBP6 and MDM2, 
respectively, were observed after siRNA co-treatment with staurosporine 
whereas combination of camptothecin with siRBBP6 and siMDM2 led to 
about 53% and 21% gene silencing, respectively (figure1.1b: A&B) 
 
The present study emphasizes the important role of p53 and Bax pro-
apoptotic genes in activating apoptosis and reducing cell proliferation. The 
effect of RBBP6 and MDM2 silencing on p53 expression in both MCF-7 and 
CAMA-1 cells is shown in figure 1.1a: C&D and figure1.1b: C&D, 
respectively. As observed in MCF-7, siRBBP6 in combination with 
camptothecin treatment led to a 13% increase in the expression of p53 
whereas siMDM2 in combination with camptothecin resulted in 31% increase 
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expression (figure1.1a: C& D). However, co-treatment with staurosporine 
showed little to no-effect in the expression of p53 after treatment with 
siRBBP6 or siMDM2 (figure1.1a: C& D). In CAMA-1 cells, there were 
about 17% and 33% up-regulation of p53 following co-treatment with 
siMDM2-staurosporine and siMDM2-camptothecin, respectively 
(figure1.1b: C&D). 
 
One important factor in the apoptosis induction is the Bax/Bcl2 ratio which 
determines whether the cells survive or die. We have observed up to double 
increase in the Bax/Bcl2 ratio following MDM2 silencing (figure1.2: B&D) 
and RBBP6 silencing (figure1.2: D) in MCF-7 and CAMA-1 cells. Bax was 
significantly increased following MDM2 and RBBP6 silencing that was 
followed by treatment with Staurosporine (figure1.2: A&C). Silencing both 
RBBP6 and MDM2 seem to have favoured Bax/Bcl2 ratio that is for 
apoptosis in both MCF-7 and CAMA-1. In MRC5 fibroblast cells that we 
considered normal cells, p53 was only slightly increased when RBBP6 and 
MDM2 silenced even when treated with both agents (figure1.2). 
 
These findings suggest that RBBP6 and MDM2 silencing were successful. 
The findings also suggest that combination of siRNAs (RBBP6 and MDM2) 
and camptothecin further reduces expression of RBBP6 and MDM2. Co-
treatment of siMDM2 and staurosporine showed further significant reduction 
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in MDM2 expression whereas for RBBP6 there was little effect on its 
expression after co-treatment with siRBBP6 and staurosporine.  The findings 
also suggest that both RBBP6 and MDM2 silencing does inducep53 
expression.  
 
 
Figure 1.1a: Relative quantification of gene expression in MCF-7 cells was performed 
using real time RT-PCR. A and B, gene expression of RBBP6 and MDM2 in cells that 
were not transfected and either not treated, treated with staurosporine or camptothecin, 
silenced with either MDM2 or RBBP6 siRNAs and treated with either staurosporine or 
camptothecin. C and D, p53 gene expression after co-treatment of MCF-7 cells with 
siRNAs targeting RBBP6 and MDM2, respectively, and the apoptosis-inducing agents 
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(staurosporine and camptothecin). The experiments were done in duplicates and the data is 
statistically significant, p-value <0.05. 
 
Figure 1.1b: Relative quantification of gene expression in CAMA-1 cells was performed 
using real time RT-PCR. A and B gene expression of RBBP6 and MDM2 in cells that 
were not transfected and either not treated, treated with staurosporine or camptothecin, 
silenced with either MDM2 or RBBP6 siRNAs and treated with either staurosporine or 
camptothecin. C and D, p53 gene expression after co-treatment of CAMA-1 cells with 
siRNAs targeting RBBP6 and MDM2, respectively, and the apoptosis-inducing agents 
(staurosporine and camptothecin). The experiments were done in duplicates and the data is 
statistically significant, p-value <0.05. 
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Figure 1.2: Relative quantification of gene expression in MCF-7 and CAMA-1 cells was 
performed using real time RT-PCR. A and C, gene expression of Bax and BCl-2 in MCF-7 
and CAMA-1, respectively, that were not transfected and either not treated, treated with 
staurosporine or camptothecin, silenced with either RBBP6-, p53- and MDM2-targeting 
siRNAs then treated with either staurosporine or camptothecin. B and D, Bax/BCl-2 ratios 
after co-treatment of MCF-7 and CAMA-1 cells, respectively, with siRNAs targeting 
RBBP6, p53 and MDM2, and the apoptosis-inducing agents (staurosporine and 
camptothecin).  
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Figure 1.3: Relative quantification of gene expression in MRC-5 cells was performed using 
real time RT-PCR. (A) shows gene expression of p53 in cells that were not treated, silenced 
with either MDM2 or RBBP6 siRNAs and then treated with either staurosporine or 
camptothecin. B and C, Bax, BCl-2 relative expression and Bax/BCl-2 ratios after co-
treatment of MRC-5 cells, respectively, with siRBBP6 and the apoptosis-inducing agents 
(staurosporine and camptothecin). 
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 Figure 1.4: Relative quantification of GAPDH gene expression in MCF-7 (blue), CAMA-
1(red) and MRC-5 (green) cells was performed as a control using real time RT-PCR 
before transfection and after transfection with either i) reagent-only, ii) siGAPDH 
(positive control) and iii) non-targeting siRNA (negative control).   
 
 
 
 
 
 
 
 
 
 
 
A
B
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4.3 Protein Expression by Western Blot Analysis 
Having shown that using quantitative PCR silencing RBBP6 and MDM2 was 
successful in mRNA, it was necessary to further confirm the success at a 
protein level because in most cases mRNA is later translated by the cell 
machinery into functional protein. In this study, western blotting was 
employed to analyse protein expression following RBBP6 and MDM2 
silencing. Briefly, cells were transfected for 48 hours with siRNAs (siRBBP6, 
sip53 and siMDM2) and then treated with either staurosporine or 
camptothecin for a further 24 hours, followed by whole cell protein extraction 
and analysis. 
 
The expression of RBBP6, MDM2 and p53 proteins was significantly 
reduced following silencing in MCF-7, CAMA-1 and MRC-5 cells with their 
respective siRNAs in comparison to protein expression in cells that were 
untreated and those that were treated with staurosporine or camptothecin 
alone (figure 2). In MCF-7, Combination of siRNAs with either 
staurosporine or camptothecin almost led to a complete repression of RBBP6 
and MDM2 proteins whereas reduction in p53 protein expression seems to be 
constant in siRNA-only and siRNA + staurosporine/camptothecin-treated 
cells (figure2.1: A-C). Silencing both RBBP6 and MDM2 followed by 
treatment with Staurosporine in MCF-7 cells resulted in an increase in bax 
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protein expression (figure2.1: D) whereas that of Bcl2 seemed to be reduced 
or remained unchanged (figure2.1: E).  
 
Expression of RBBP6, p53 and MDM2 proteins after silencing RBBP6 gene 
were also measured in CAMA-1 and MRC-5 cell lines (figure2.2: A- B).  
Expression of RBBP6 seems to decrease significantly in CAMA-1 cell lines 
following treatment with camptothecin. However, treatment with 
staurosporine slightly lowers RBBP6 expression in CAMA-1 cells 
(figure2.2: A). siRBBP6 lowers RBBP6 expression and when combined with 
camptothecin the RBBP6 protein is almost completely silenced (figure2.2: 
A). MDM2 expression in CAMA-1 cells is not affected much by 
camptothecin, nor RBBP6 silencing and siRBBP6-camptothecin treatment. 
However, treatment with staurosporine or staurosporine + siRBBP6 lowers 
the expression of MDM2 (figure2.2: A).  
 
As expected, RBBP6 silencing up-regulates the expression of p53. However, 
combination of siRBBP6 and either staurosporine or camptothecin does not 
seem to alleviate p53 expression (figure2.2: A). It was also noted that 
staurosporine treatment lowers the expression of p53 as well (figure2.2: A). 
In MRC-5 cells MDM2 expression remains almost the same throughout 
treatment (figure2.2: B). RBBP6 expression decreases steadily and p53 
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remains constantly up-regulated after siRBBP6 treatment, siRBBP6+STS and 
siRBBP6+CPT (figure2.2: B).  
 
SiRBBP6 in MCF-7, CAMA-1 and MRC-5 cells and siMDM2 in MCF-7 led 
to an up-regulation of p53 protein (figure2.1: A-C and figure2.2 A-B) 
whereas sip53 caused MDM2 down-regulation (figure2: B). These findings 
suggest that there might be a relationship between RBBP6, MDM2 and p53 at 
both mRNA and protein level. 
 
 Figure 2.1: Protein expression in MCF-7 cells was performed using western blot 
technique. GAPDH was used to confirm that an equivalent amount of protein was loaded 
into each well. A, protein expression of RBBP6 and p53 in cells that were either not 
treated or co-treated with RBBP6 siRNAs and staurosporine (STS) or camptothecin 
(CPT). B, p53 and MDM2 protein expression after co-treatment of MCF-7 cells with 
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siRNA targeting p53 and the apoptosis-inducing agents (staurosporine and camptothecin). 
C, MDM2 and p53 protein expression after silencing with siRNAs targeting MDM2 and 
the apoptosis-inducing agents (staurosporine and camptothecin). D and E, protein 
expression of bax and BCl-2, respectively, in cells that were either not treated or co-treated 
with RBBP6-, p53- and MDM2-targeting siRNAs and staurosporine (STS) or 
camptothecin (CPT). 
 
 
Figure 2.2: Protein expression in CAMA-1 (A) and MRC-5 (B) cells was performed using 
western blot technique. MDM2, RBBP6 and p53 protein expression was analysed in 
CAMA-1 and MRC-5 cells after co-treatment with RBBP6 siRNA and staurosporine 
(STS) or camptothecin (CPT).  
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Figure 2.3: Statistical analysis of western blot protein expression analysis in MCF-7 cell line. T-test was 
used to generate p-values in order to compute the difference between treated and untreated scores. A, B, 
C, D, E and F, statistical analysis between untreated and silenced and between treated/silenced + treated 
(as described on y and x-axes). * indicates p ≤ 0.05, ** indicates p ≤ 0.01, *** indicates p ≤ 0.001 and ns 
indicates p ≥ 0.05. 
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Figure 2.4: Statistical analysis of western blot protein expression (bax and bcl-2) analysis in CAMA-1 cell 
line. T-test was used to generate p-values in order to compute the difference between treated and untreated 
scores. G, H, I, J, K and L, statistical analysis between untreated and silenced and between 
treated/silenced + treated (as described on y and x-axes). * indicates p ≤ 0.05, ** indicates p ≤ 0.01, *** 
indicates p ≤ 0.001 and ns indicates p ≥ 0.05. 
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Figure 2.5: Statistical analysis of western blot protein expression analysis in CAMA-1 cell line (M, 
N and O) and in MRC-5 cell line (P, Q and R). T-test was used to generate p-values in order to 
compute the difference between treated and untreated scores, untreated and silenced and between 
treated/silenced + treated (as described on y and x-axes). * indicates p ≤ 0.05, ** indicates p ≤ 0.01, 
*** indicates p ≤ 0.001 and ns indicates p ≥ 0.05. 
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4.4 Analysis of Cell Growth after Co-treatment 
 
The objective of this section was to monitor the effect of RBBP6 silencing 
and its related genes on cell viability of cultured adherent cells. To 
accomplish this, the xCELLigence real time cell analyser was used which is a 
non-invasive label-free technique that is based on an increase in electrode 
impedance in response to cell adhesion and spreading on the surface of a 
biocompatible gold-coated 16-well E-plate.  The cells were monitored over a 
period of about 2 days with 24 hours of silencing-only followed by another 
24 hours of co-treatment with either staurosporine or camptothecin.   
 
In response to gene silencing and induction of apoptosis with either 
staurosporine or camptothecin, we verified the growth inhibitory effect of 
siRBBP6, siMDM2 and sip53 (100nM) in MCF-7and CAMA-1 breast cancer 
cells (figure 3.1 and 3.2). Growth curves were normalised to the cell index 
(CI) at the last measured time point before compound addition for each well. 
MCF7 growth curve, which is presented in figure 3.1 showed a significant 
reduction in cellular growth after silencing with siRBBP6 and siMDM2 
whereas sip53 reduces cell growth at a slower rate. Combination of siRNAs 
and the apoptosis-inducing agents (staurosporine or camptothecin) further 
reduces cell growth as shown in figure 3.1: B and C. Staurosporine reduced 
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cell growth at a much faster rate as compared to camptothecin (figure 3.1: B 
and C).  
 
In CAMA-1 breast cancer cells, RBBP6-knock down population shows a 
higher rate of growth inhibition following treatment with camptothecin as 
compared to the p53- and MDM2-knock down populations (figure 3.2: E).  
When comparing results obtained from breast cancer cells (MCF-7 and 
CAMA-1) to those obtained from MRC-5 fibroblasts, almost similar pattern 
of growth inhibition was observed however at a minimal level (figure3.3: G-
I). Staurosporine and siRBBP6 did not have as much effect as in MCF7 cells 
(figure 3.3: I).     
 
These findings suggest that both co-treatments (siRNAs + staurosporine and 
siRNAs + camptothecin) induce cell death. However, the siRNAs + 
staurosporine combination might be more potent in the cells as seen by the 
rapid fall in cellular growth.  
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Figure 3.1: Cell growth of MCF-7 cells was analysed using the xCELLigence system which 
relies on the generation of electrical impedance as cell growth by 16-well plates coated with a 
gold microelectron covering at the base of each well. The y-axis shows normalised cell index 
or cell adhesion over a period of about 48 hours (x-axis). The growth patterns highlighted in 
blue show cells that are not treated; those highlighted in green, light blue and pink show cells 
that were transfected with siRBBP6, siMDM2 and sip53, respectively. A shows growth 
curves of cell populations that were silenced only and not treated and treatment with 
staurosporine or camptothecin (B and C, respectively) was introduced 24 hours post 
transfection   
. 
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Figure 3.2: Cell growth of CAMA-1 cells was analysed using the xCELLigence system 
which relies on the generation of electrical impedance as cell growth by 16-well plates coated 
with a gold microelectron covering at the base of each well. The y-axis shows normalised cell 
index or cell adhesion over a period of about 48 hours (x-axis). The growth patterns 
highlighted in orange show cells that were exposed to transfection reagent only and those 
highlighted in green, light blue and pink show cells that were transfected with siRBBP6, 
siMDM2 and sip53, respectively. D shows growth curves of cell populations that were 
silenced only and not treated and treatment with staurosporine or camptothecin (E and F, 
respectively) was introduced 24 hours post transfection. 
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Figure 3.3: Cell growth of MRC-5 cells was analysed using the xCELLigence system which 
relies on the generation of electrical impedance as cell growth by 16-well plates coated with a 
gold microelectron covering at the base of each well. The y-axis shows normalised cell index 
or cell adhesion over a period of about 48 hours (x-axis). The growth patterns highlighted in 
orange show cells that were exposed to transfection reagent only and those highlighted in 
green, light blue and pink show cells that were transfected with siRBBP6, siMDM2 and 
sip53, respectively. G shows growth curves of cell populations that were silenced only and 
not treated and treatment with staurosporine or camptothecin (H and I, respectively) was 
introduced 24 hours post transfection 
 
 
4.5 Apoptosis Detection 
As shown in the previous section, gene silencing coupled with either of the 
apoptosis inducers (staurosporine or camptothecin) led to reduced cell 
viability in breast cancer cells MCF-7 and CAMA-1. To identify whether the 
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observed cell death was as a result of apoptosis or necrosis, flow cytometry 
analysis was used. Annexin V and PI staining make flow cytometry an 
effective technique to distinguish between necrosis, early and late apoptosis 
in cultured cells. In this section, we measured apoptosis following co-
treatment with siRNAs (siRBBP6, sip53, and siMDM2) and apoptosis 
inducers.  
Analysis by flow cytometry revealed that the percentage of apoptotic cells 
following treatment with camptothecin and staurosporine was significantly 
increased in MCF-7 cells to 53.2% and 55.9% respectively (p˂0.05) (figure4: 
c and d) in comparison to untreated cells at only 0.8% (figure4: b). siRBBP6 
significantly increased apoptosis in MCF-7 cells treated with camptothecin 
(20.7% increment). However, only 8.8% increase in apoptosis was observed 
in MCF-7 cells that were treated with siRBBP6 and staurosporine (figure5: e 
and f). MDM2 silencing in MCF-7 significantly induced apoptosis in 
camptothecin-treated cells by 26.6% as compared to that of staurosporine 
where only 0.5% increase in apoptosis was observed (figure5: g and h). 
sip53 reduces camptothecin-induced and staurosporine-induced apoptosis by 
26% and 30.7%, respectively in MCF-7 (figure6: I and j) which was far less 
than those of MDM2 and RBBP6.  
 
In CAMA-1 cells, silencing RBBP6 in combination with staurosporine 
decreased the level of staurosporine-induced apoptosis from 59.1% to 50.7% 
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whereas combination of siRBBP6 with camptothecin shifted camptothecin-
induced apoptosis from 56% to 61% (figure8: B-F). Similarly, MDM2 
silencing led to a negative shift of apoptosis when combined with 
staurosporine (from 59.1% to 54.2) and a positive shift when combined with 
camptothecin (56.1% to 67.3%) (figure8: J-L). Untreated CAMA-1 cells 
showed only 0.3% apoptosis. We further observed that apoptosis induction in 
CAMA-1 cells that were p53-silenced, sip53+STS- and sip53+CPT-treated 
was minimal (46.9%, 39.1% and 28.6%, respectively) in comparison to 
apoptosis induced in CAMA-1 cells that were treated with only staurosporine 
or camptothecin (59.1% and 56.1,  respectively) (figure8: G-I).  
 
Apoptosis induction in MRC-5 fibroblast was fairly low following treatment 
with staurosporine or camptothecin (15.3% and 18.7%, respectively) as 
compared to the one observed in MCF-7 and CMA-1 cells (figure9: B and 
C). Only 2.5% apoptosis was observed in untreated MRC-5 cells. Silencing 
MRC-5 with siRBBP6, sip53 and siMDM2 induced 15.8%, 12.3% and 20.5% 
apoptosis, respectively (figure9 and 10), whereas combination with 
staurosporine led to 13.5%, 13.3% and 12.6% apoptosis induction, 
respectively (figure 9 and 10). Combination of siRBBP6, sip53 and siMDM2 
with camptothecin in MRC-5 led to 12%, 14.8% and 15.4% apoptosis, 
respectively (figure 9 and 10).  
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Double silencing with siRBBP6 and sip53 in both CAMA-1 and MCF-7 cells 
showed a slightly lower apoptosis in comparison to siRBBP6 only (figure 
11). siRBBP6/sip53 double silencing led to 36.7% apoptosis in MCF-7 and 
39.4% apoptosis in CAMA-1 cells. Co-treatment with staurosporine led to 
50.7% apoptosis in MCF-7 and 50.8% in CAMA-1 cells whereas co-
treatment with camptothecin led to 50.9% and 41.8% apoptosis in MCF-7 and 
CAMA-1 cells, respectively (figure 11).  
        
   
 
Figure 4: Apoptosis of MCF-7 cells was analysed using flow cytometer with annexin V and PI. Upper left 
quadrants show necrotic cells which stain positive for PI and negative for annexin V, upper right 
quadrants show cells undergoing late apoptosis with positive staining for both PI and annexin V. Lower 
right quadrants show cells undergoing early apoptosis and are staining positive for annexin V and negative 
for PI; and lastly the lower left quadrants show viable cells. (a) Gating of cells showing the side and 
(e) 
P Moela: MSc Dissertation 
60 
 
forward scatter. (b)  Shows cells before treatment, (c) and (d) show cells after treatment with 0.25μΜ 
staurosporine and 0.25μM camptothecin, respectively. (e) Shows cells after transfection with siRBBP6-
only.  
 
 
Figure 5: Apoptosis of MCF-7 cells was analysed using flow cytometer with annexin V and PI. (e) MCF-7 
cells after co-treatment with 100nM RBBP6 siRNA and 0.25μΜ staurosporine and (f) MCF-7 cells after co-
treatment with 100nM RBBP6 siRNA and 0.25μM camptothecin. (g) MCF-7 cells after co-treatment with 
100nM MDM2 siRNA and 0.25μΜ staurosporine and (h) MCF-7 cells after co-treatment with 100nM 
MDM2 siRNA and 0.25μM camptothecin.  
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Figure 6: Apoptosis of MCF-7 cells was analysed using flow cytometer with annexin V and PI. (h) MCF-7 
cells after co-treatment with 100nM p53 siRNA and 0.25μΜ staurosporine and (i) MCF-7 cells after co-
treatment with 100nM p53 siRNA and 0.25μM camptothecin.  
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Figure 7: Apoptosis of CAMA-1 cells was analysed using flow cytometer with annexin V and PI. (A) 
apoptosis in untreated cells, B and C cells after treatment with staurosporine and camptothecin, respectively. 
D, E, and F, apoptosis in cells co-treated with 100nM siRBBP6, 100nM siRBBP6 + 0.25μΜ staurosporine 
and 100nM siRBBP6 + 0.25μΜ camptothecin, respectively.  
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Figure 8: Apoptosis of CAMA-1 cells was analysed using flow cytometer with annexin V and PI. G, H 
and I, apoptosis in cells co-treated with 100nM sip53, 100nM sip53 + 0.25μΜ staurosporine, and 100nM 
sip53 + 0.25μΜ camptothecin, respectively, and J, K and L, apoptosis in cells co-treated with 100nM 
siMDM2, 100nM siMDM2 + 0.25μΜ staurosporine and 100nM siMDM2 + 0.25μΜ camptothecin, 
respectively. 
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 Figure 9: Apoptosis of MRC-5 cells was analysed using flow cytometer with annexin V and PI. A apoptosis in 
untreated cells, B and C cells after treatment with staurosporine and camptothecin, respectively. D, E, and F, 
apoptosis in cells co-treated with 100nM siRBBP6, 100nM siRBBP6 + 0.25μΜ staurosporine and 100nM 
siRBBP6 + 0.25μΜ camptothecin, respectively.  
P Moela: MSc Dissertation 
65 
 
Figure 10: Apoptosis of MRC-5 cells was analysed using flow cytometer with annexin V and PI. G, H and I, 
apoptosis in cells co-treated with 100nM sip53, 100nM sip53 + 0.25μΜ staurosporine, and 100nM sip53 + 
0.25μΜ camptothecin, respectively, and J, K and L, apoptosis in cells co-treated with 100nM siMDM2, 100nM 
siMDM2 + 0.25μΜ staurosporine and 100nM siMDM2 + 0.25μΜ camptothecin, respectively. 
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Figure 11: Apoptosis of MCF-7 (A, B, and C) and CAMA-1 (D, E, and F) cells double-silenced with 
siRBBP6 and sip53 and co-treated with either 0.25μΜ staurosporine or 0.25μΜ camptothecin was analysed 
using flow cytometer (annexin V and PI). A and D, shows cells double-silenced with siRBBP6/sip53, B and 
E shows cell co-treated with siRBBP6/sip53 + STS, and C and F shows cells co-treated with 
siRBBP6/sip53 + CPT. 
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Figure12: Statistical analysis of flow cytometry-obtained apoptosis (%) in MCF-7 cell line. T-test was used 
to generate p-values in order to compute the difference between treated and untreated scores. A, B and C, 
statistical analysis between untreated and silenced and between treated and silenced + treated in MCF-7 cells. 
* indicates p ≤ 0.05, ** indicates p ≤ 0.01, *** indicates p ≤ 0.001 and ns indicates p ≥ 0.05. 
 
P Moela: MSc Dissertation 
68 
 
 
Figure 13: Statistical analysis of flow cytometry-obtained apoptosis (%) in CAMA-1 cell line. T-test was 
used to generate p-values in order to compute the difference between treated and untreated scores. D, E and 
F, statistical analysis between untreated and silenced and between treated and silenced + treated in MCF-7 
cells. * indicates p ≤ 0.05, ** indicates p ≤ 0.01, *** indicates p ≤ 0.001 and ns indicates p ≥ 0.05. 
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Figure 14: Statistical analysis of flow cytometry-obtained apoptosis (%) in MRC-5 cell line. T-test was 
used to generate p-values in order to compute the difference between treated and untreated scores. G, H 
and I, statistical analysis between untreated and silenced and between treated and silenced + treated in 
MCF-7 cells. * indicates p ≤ 0.05, ** indicates p ≤ 0.01, *** indicates p ≤ 0.001 and ns indicates p ≥ 
0.05. 
 
P Moela: MSc Dissertation 
70 
 
 
Figure 15: Statistical analysis of flow cytometry-obtained apoptosis (%) in MCF-7 and CAMA-1 cell lines. 
T-test was used to generate p-values in order to compute the difference between treated and untreated 
scores. The statistical analysis was computed between double-silenced and co-treatment with either 
staurosporine or camptothecin. * indicates p ≤ 0.05, ** indicates p ≤ 0.01, *** indicates p ≤ 0.001 and ns 
indicates p ≥ 0.05. 
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                             Chapter 5: Discussion and Conclusions 
 
Discussion 
 
Several E3 enzymes are associated with cancer development and are therefore 
highly expressed in a number of tumours (Chen et al, 2006). RBBP6 has been 
identified as an E3 ubiquitin ligase that is markedly up-regulated in tumours of 
the lung (Motadi et al, 2011). Because RBBP6 possesses a p53 binding domain, 
the p53 tumour suppressor is prone to ubiquitination by the ring finger domain 
of RBBP6, thus leading to cancer progression (Malloy et.al, 2012; Vassilev et 
al, 2004). RBBP6 therefore serves as a hallmark target in the development of 
anticancer therapeutics and findings in this study reveal how a synergistic effect 
of two biological compounds could become a potential treatment against breast 
cancer by targeting RBBP6.  
 
We demonstrated at both the mRNA and protein level that it is possible to 
markedly silence the expression of RBBP6 in human breast cancer cells (MCF-
7 and CAMA-1) using RNA interference. We further demonstrated that 
combinational therapy of siRBBP6 and either camptothecin or staurosporine 
further reduces expression of RBBP6 and lead to reduction in cell proliferation 
(figure 1). However, siRBBP6 in combination with staurosporine does not 
significantly reduce RBBP6 gene expression. These differences in the effects of 
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these two combinational therapies (RBBP6 siRNA/staurosporine and RBBP6 
siRNA/camptothecin) on RBBP6 expression may be attributable to the fact that 
the two apoptosis-inducing agents possess different mechanisms of apoptosis 
induction. 
Camptothecin acts as a topoisomerase I inhibitor thus causing DNA strand 
breaks during the S-phase of the cell cycle which leads to apoptosis in cancer 
(Arakawa et al., 2009). The mechanism by which staurosporine uses to induce 
apoptosis is not well understood. However, it is suspected that it uses its protein 
kinase inhibiting function to mediate translocation of bax from the cytosol to 
mitochondria where it causes the  release of cytochrome c from the outer 
mitochondrial membrane (Xue et al., 2003; Motadi et al 2007). Silencing of 
RBBP6 in these cells markedly enhanced the level of apoptosis induced by 
camptothecin. However, apoptosis induced by staurosporine was not 
significantly enhanced by RBBP6 silencing. The results also strongly suggest 
that the enhanced apoptosis is as a result of the synergistic effect between 
RBBP6 siRNA and camptothecin as treatment with camptothecin alone (or 
siRNA alone) inducing less apoptosis.   
 
p53 induces apoptosis by transcriptionally activating bax and causing its 
translocation to the mitochondria where it prorates the outer mitochondrial 
membrane (Shen and White, 2001). P53-silenced cells were not undergoing as 
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much apoptotic cell death as those that were RBBP6-silenced and from this it is 
arguable that some of the observed apoptosis might be attributed to some p53-
mediated pathway. These findings suggest that by blocking the gene expression 
of both MDM2 and RBBP6 the activation of other proapoptotic genes is 
promoted, leading to the activation and upregulation of different intracellular 
signaling pathways, including BCl-2 gene family, inflammatory caspases and 
death receptors (Porichi et al 2009;  Morissette et al 2007). These signalling 
pathways promote p53 mediated cell death. 
 
Under normal physiological conditions, wild type TP53 tumour suppressor has 
a short half-life due to its targeted degradation by MDM2 E3 ubiquitin ligase 
(Bai and Zhu, 2006). This auto-regulatory feedback loop keeps TP53 under 
tight regulation to maintain normal cell growth and prevent tumorigenesis 
(Malloy et.al, 2012; Vassilev et al, 2004). In response to stress signals such as 
DNA damage, activated TP53 stimulates genes such as p21 and Bax which are 
responsible for the induction of cell cycle arrest and apoptosis, respectively (Bai 
and Zhu, 2006). Inhibition of RBBP6 led to overexpression of the p53 tumour 
suppressor at both the mRNA and protein level. This suggests that by silencing 
RBBP6 we were able to block the interaction between RBBP6 and p53 and thus 
prevented p53 degradation. 
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During their auto-regulatory feedback loop, p53 activates MDM2 which in turn 
has the ability to block the transactivation activity of p53 by tightly binding the 
p53 protein (Malloy et.al, 2012). MDM2 is also involved in the nuclear 
transport of p53 and also serves as an E3 ubiquitin ligase that promotes 
degradation of p53 (Vassilev et al., 2012). We demonstrated in this study that 
by tempering with the p53:MDM2 auto-regulatory feedback loop, i.e. silencing 
MDM2, also frees p53 as evidenced by the up-regulation of both p53 mRNA 
and p53 protein (figure 1) and the fact that p53 silencing leads to MDM2 down-
regulation suggests that the p53:MDM2 interaction does exist and it 
compromises the function of p53 during cancer development (Shangary S and 
Wang S 2008). These findings suggest that in the absence of RBBP6 and the 
p53:MDM2 interaction p53 degradation by the E3 ubiquitin ligases is 
abrogated, thus leading to p53-mediated apoptosis. Normal skin fibroblasts 
were less responsive to the co-treatment and this somehow suggests that 
silencing RBBP6 does not exhibit any cytotoxicity to noncancerous cells.  
 
We showed a good correlation between cellular growth reduction and apoptosis 
induction in MCF-7 cells, for example siRBBP6 combined with camptothecin 
led to a significant cellular growth rate reduction and an increase in apoptosis 
induction in comparison to cells that were untreated or treated with 
camptothecin only. However combination of siRBBP6 with staurosporine led to 
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a much faster reduction in growth rate of both MCF-7 and CAMA-1 cells 
(figure 3.1 and 3.2). The observed difference in the potency of camptothecin 
and staurosporine on cell growth may be attributable to the fact that the two 
agents induce apoptosis using different mechanisms. We have shown that 
camptothecin induces a much higher apoptosis than staurosporine when 
combined with siRBBP6 and this may be due to the fact that camptothecin 
interacts directly with proapoptotic genes in order to induce apoptosis (Zeng et 
al, 2012). Wild type p53 has been shown to enhance camptothecin-induced 
apoptosis (Zhang et al, 2000 and Li et al, 2000) and this may also explain the 
observed enhanced apoptosis in cells co-treated with siRBBP6+camptothecin. 
 
Interestingly, we also showed that sip53 combined with either camptothecin or 
staurosporine leads to a slight increase in cell growth in comparison to co-
treatment with siRBBP6 or siMDM2 and either of the agents (figure 3.1). This 
observation may suggest that p53 is required in the induction of cell death and 
to explore this further, apoptosis detection was carried out in p53-knockdown 
MCF-7 cells. We showed that there is minimal apoptosis induction in p53-
silenced cell population in comparison to cells co-treated with either siMDM2 
or siRBBP6. P53 is involved in the induction of apoptosis via the intrinsic 
apoptotic pathway by promoting transcription; translocation and 
oligomerization of bax on the outer mitochondrial membrane in order to 
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facilitate cytochrome c release (Bai and Zhu, 2006) and these findings suggest 
that silencing p53 reduces p53-mediated apoptosis. 
 
Cellular growth studies have shown that CAMA-1 cells deteriorate in response 
to siMDM2+ camptothecin and siRBBP6 + camptothecin co-treatments. 
However, in comparison to MCF-7, growth reduction lasted for a short period 
of time before the cells would recover and this may be due to the fact that 
CAMA-1 cells are metastatic which makes them more aggressive and less 
responsive to the co-treatment (Kenny et al, 2007). The fact that there was no 
increase in cell growth following sip53 co-treatment may suggest that CAMA-1 
cells do not depend mainly on p53 to undergo cell death. Due to their 
aggressiveness, CAMA-1 generally underwent less apoptosis in comparison 
with that observed in MCF-7. The co-treatment may be less cytotoxic to normal 
cells because according to our findings there was little to no effect in terms of 
apoptosis induction or cell growth reduction in MRC-5 fibroblasts (figure 3.3, 9 
and 10). We have also shown that p53-knockdown in MCF-7 and CAMA-1 
cells that were also silenced with siRBBP6 induced a slightly lower apoptosis 
following co-treatment with either staurosporine or camptothecin. p53 might be 
responsible for some of the observed apoptosis induction in RBBP6-silenced 
cells and this may be due to the fact that siRBBP6 has led to p53 up-regulation 
in both cell lines.  
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Conclusion 
p53 could promote the convergence of the extrinsic and intrinsic apoptotic 
pathways, including in MCF7 breast cancer cells. The present study provides 
early insight into the mechanisms of RBBP6 pathways in mediating p53 in 
breast cancer cells as the mRNA and protein expression data show. 
Manipulating the expression of the RBBP6 and MDM2 genes is required for the 
induction of apoptosis by different Bcl-2 gene family members. Therefore, these 
results provide a promising path to understanding further the role of RBBP6 in 
cancer development and treatment.  
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